AstraZeneca's Imfinzi trial shows 'significantly improved' event-free survival rates
Sharecast
Published Mar 09, 2023 09:11
AstraZeneca's Imfinzi trial shows 'significantly improved' event-free survival rates
Sharecast - AstraZeneca said results of the Imfinzi trial showed that treatment with the drug both before and after surgery "significantly increased" the time patients live without recurrence or progression events.
Results from the final pathologic complete response and major pathologic response analyses were consistent with previously announced positive results, and the trial will continue as planned to assess key secondary endpoints including disease-free survival and overall survival.
AstraZeneca'a Susan Galbraith said: "Patients with resectable non-small cell lung cancer face unacceptably high rates of recurrence, despite treatment with chemotherapy and surgery. We have shown that adding Imfinzi both before and after surgery significantly increased the time patients live without recurrence or progression events. We will continue to follow patients for overall survival."
As of 0910 GMT, AstraZeneca shares were up 0.50% at 10,876.0p.
Reporting by Iain Gilbert at Sharecast.com
Read more on Sharecast.com
Get The App
Written By: Sharecast
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.